Zonisamide: newer antiepileptic agent with multiple mechanisms of action

References

• Leppik IE, Willmore LJ, Homan RW et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 14 (2), 165–173 (1993).
   Google Scholar
• •Reports data from well-controlled, double-blind studies.
   Google Scholar
• Leppik IE. Zonisamide. Epilepsia 40\(Suppl. 5), S23—S29 (1999).
   Google Scholar
• Zonegran®. Package insert. Eisai Co, NJ, USA.
   Google Scholar
• Faught E, Ayala R, Montouris GG et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57 (10), 1774–1779 (2001).
   PubMed Web of Science ®Google Scholar
• •Reports data from well-controlled, double-blind studies.
   Google Scholar
• Schmidt D, Jacob R, Loiseau P et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 15(1), 67–73 (1993).
   Google Scholar
• Masuda Y, Ishizaki M, Shimizu M. Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev 4, 341–360 (1998).
   PubMedGoogle Scholar
• Hasegawa H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. CUIT: Res. Opin. 20, 577–580 (2004).
   PubMed Web of Science ®Google Scholar
• Krusz J. Treatment of chronic pain with zonisamide. Pain Prac. 3,317–320 (2003).
   PubMedGoogle Scholar
• Masuda Y, Karasawa T, Shiraishi Y et aL 3- Sulfamoylmethy1-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforschung30 (3), 477–483 (1980).
   Google Scholar
• Rock D, MacDonald RL, Taylor CO. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD-810, CI-912), a novel anticonvulsant. Epilepsy Res. 3,138-143 (1989).
   Google Scholar
• Svensson C, Cowen E, Gaspari A. Cutaneous drug reactions. Pharmacol. Rev 53,357–379 (2000).
   Google Scholar
• Knowles S, Shapiro L, Shear N. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of sulfa' allergy. Drug Sal. 24,239–247 (2001).
   Google Scholar
• Reilly T, Ju C. Mechanistic perspectives on sulfanamide-induced cutaneous drug reactions. Cur. Opin. Allergy Clin. ImmunoL 2,307–315 (2002).
   PubMed Web of Science ®Google Scholar
• Shah J, Shellenberger K, Canafax DM. Zonisamide. Chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic Drugs. Fifth Edition. Levy R, Mattson RH, Meldrum BS (Eds). Lippincott Williams & Wilkins, PA, USA, 873–879 (2002).
   Google Scholar
• Taylor C, McLean JR, Brochenbrader HN etal. Zonisamide (AD-810, CI-912). In: New Anticonvulsant Drugs. Meldrum B, Porter RJ (Eds). John Libbey, London, UK, 277–294 (1986).
   Google Scholar
• Matsumoto K, Miyazaki H, Fujii T et al. Absorption, distribution and excretion of 3-(sulfamoyl (14C] -methyl)-1,2-benzisoxazole (AD-810) in rats, dogs, and monkeys and AD-810 in man. Arzneimittelforschung 33, 961–968 (1983).
   PubMed Web of Science ®Google Scholar
• Ito T, Yamaguchi T, Mizyazaki H et al. Arzneimittel-Forschung 32,1581–1586 (1982).
   Google Scholar
• Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther. Drug Monitor 20,593–597 (1998).
   PubMed Web of Science ®Google Scholar
• Peters D, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapuetic potential in epilepsy. Drugs 45, 760–787 (1993).
   Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31, 29–46 (1996).
   PubMed Web of Science ®Google Scholar
• Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs: zonisamide. In: Antiepileptic Drugs. Levy R, Mattson RH, Meldrum BS (Eds). Raven Press, NY, USA, 1011–1023 (1995).
   Google Scholar
• Ojemann L, Shastri RA, Wilensky AJ et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther. Drug Monitor 8, 293–296 (1986).
   Google Scholar
• Rho J, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 40, 1471–1483 (1999).
   PubMed Web of Science ®Google Scholar
• Dichter M. Mechanisms of action of new antiepileptic drugs. In:Antiepileptic Drug Development. Advances in Neurology French J, Dichter MA, Leppik IE (Eds). Lippincott-Raven Publishers, PA, USA, 1–9 (1998).
   Google Scholar
• Macdonald R. Zonisamide. Mechanisms of action. In: Antiepileptic Drugs. Fifth Edition. Levy J, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA (2002).
   Google Scholar
• Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockage by zonisamide. Epilepsia 38,36 (1995).
   Google Scholar
• Suzuki S, Kawakami K, Nishimura S et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12,21–27 (1992).
   PubMed Web of Science ®Google Scholar
• MacDonald BK, Cockerell OC, Sander JW et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123(Pt 4), 665–676 (2000).
   PubMed Web of Science ®Google Scholar
• Okada M, Kawata Y, Mizuno K etal. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br. J. PharmacoL 124,1277–1285 (1998).
   Google Scholar
• Kawai M, Hiramatsu M, Endo A et al. Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from hippocampal slices of El mice. Neurosciences 20,115–119 (1994).
   Google Scholar
• Sobieszek G, Borowicz K, Kimber-Trojnar Z et al. Zonisamide: a new antiepileptic drug. Polish J. PharmacoL 55,683–689 (2003).
   PubMedGoogle Scholar
• Gluck M, Santana L, Granson H et al. Novel dopamine releasing response of an anticonvulsant agent with possible anti-Parkinson's activity. J Neural Trans. 111, 713–724 (2004).
   PubMed Web of Science ®Google Scholar
• Okada M, Kaneko S, Hirano T etal. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res. 13,113-119 (1992).
   Google Scholar
• Murata M. Novel therapeutic effects of the anticonvulsant, zonisamide, on Parkinson's disease. CUIT: Pharm. Des. 10,687–693 (2004).
   Google Scholar
• Minato H, Kikuta C, Fuijtani B et al. Protective effect of zonisamide, an antiepileptic drug against transient focal cerebral ischaemia with middle cerebral artery occlusion-preperfusion in rats. Epilepsia 38,975–980 (1997).
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Higuchi H, Nigami H et al. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur. J PharmacoL 257,131–135 (1994).
   PubMed Web of Science ®Google Scholar
• Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 30,153–158 (1998).
   Google Scholar
• Mori A, Noda Y, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res. Commun. MoL PathoL PharmacoL 105,23–33 (1999).
   Google Scholar
• Owen A, Ijaz S, Miyashita H et al. Zonisamide as neuroprotective agent in an adult gerbil model of global forebrain ischaemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 770,115–122 (1997).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Hiramatsu M, Willmore LI. Zonisamide reduces the increase in 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia 41,1091–1094 (2000).
   Google Scholar
• Sackellares J, Ramsay RE, Wilder BJ, Browne TR III, Shellenberger MK. Randomized, controlled, clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 45, 610–617 (2004).
   Google Scholar
• •Reports data from well-controlled, double-blind studies.
   Google Scholar
• Yagi K, Seino M. Methodological requirements for clinical tirals in refractory epilepsies — our experience with zonisamide. Frog. Neuro-PsychopharmacoL Biological-Psychiatry16,79–85 (1992).
   PubMed Web of Science ®Google Scholar
• Seino M, Ohkuma T, Miyasaka M et al. Clinical efficacy and safety of a new antiepileptic drug, zonisamide: a multi-institutional phase three study. Clin. Psych. 30,471–482 (1988).
   Google Scholar
• French J, Kanner,AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs. II: treatment of refractory epilepsy. Report of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45,410–423 (2004).
   Google Scholar
• Seino M, Ito T. Zonisamide. In: Epilepsy' a Comprehensive Textbook. Engel J Jr (Ed.). Lippincott-Raven, PA, USA, 1619–1626 (1997).
   Google Scholar
• Lee B. Zonisamide. Adverse effects. In:Antiepileptic Drugs. Fifth Edition. Levy R, Mattson RH, Meldrum BS (Eds). Lippincott Williams & Wilkins, PA, USA (2002).
   Google Scholar
• Okumura A, Hayakawa F, Kuno K et al. Oligohidrosis caused by zonisamide. No to Hattatsu 28,44–47 (1996).
   PubMedGoogle Scholar
• Hosoda N, Niura H, Shirai H etal. Clinical study on oligohidrosis in patients treated with zonisamide. Shonika Rinsyo 49, 2445–2449 (1996).
   Google Scholar
• Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs 18, 133–156 (2004).
   PubMed Web of Science ®Google Scholar
• Glauser T, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J. Child Neurology 17,87–96 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nagai T, Ono J et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 38, 1035–1038 (1997).
   PubMed Web of Science ®Google Scholar
• Lotze T, Wilfong, A. Zonisamide treatment for symptomatic infantile spasms. Neurology 62,296–298 (2004).
   Google Scholar
• Dipiro J, Talbert R. Pain management. In: Pharmacotherapy: a Pathophysiologic Approach. Fifth Edition. McGraw-Hill, NY, USA, 113–115 (2002).
   Google Scholar
• Smith T. Zonisamide improves total headache time and headache index in refractory chronic daily headache. Pain Clinic 16,17–20 (2004).
   Google Scholar
• Bialer M, Johannessen S, Kupferberg H et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31–71 (2002).
   PubMed Web of Science ®Google Scholar
• Gadde K, Franciscy DM, Wagner H et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289, 1820–1825 (2003).
   PubMed Web of Science ®Google Scholar
• •Reports data from well-controlled, double-blind studies.
   Google Scholar
• Kim C. Zonisamide effective for weight loss in women. j Farm Prac. 52,600–601 (2003).
   PubMed Web of Science ®Google Scholar
• Nakanishi I, Kohmoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to anti-Parkinsonian medication. Brain Nerve 55,685–689 (2003).
   PubMedGoogle Scholar
• Murata M, Hasegawa H, Kanazawa I. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson's disease. Move. Dis. 19\(Suppl. 9), S198 (2004).
   Google Scholar
• Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res. 41,397–399 (2001).
   Google Scholar
• Nakanishi I, Kohmoto J, Miwa H et al. Effectiveness of zonisamide on parkinsonian tremor: A pilot cross-over study in comparison with trihexyphenidyl. Move. Dis. 19 (Suppl. 9), S147 (2004).
   Google Scholar
• Patsalos P, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2, 347–356 (2003).
   PubMed Web of Science ®Google Scholar